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models, and represents those where cost is the main determinant of outcomes. The 
latter includes the more developed Shanghai model which encompasses a more 
holistic approach with consideration for the quality, patent status and degree of 
innovation of a medicine. Analysis of published tender results shows a significant 
variation between the resultant prices in different provinces, with as much as 50% 
difference between the tender price and MRP set by the NDRC. Price erosion is 
greatest for generic medicines and those where a larger degree of competition 
exists, indicating that market forces ultimately have the greatest effect on tendering 
outcomes. ConClusions: Our results demonstrate the large degree of variation 
between tendering processes in China. Although “price focused” models typically 
result in high downwards pricing pressure, “quality focused” models are more recep-
tive of innovative medicines, thus, achieving price premiums is possible.
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objeCtives: To study the Regulatory reforms and its impact on Clinical Trials in 
India. The present study involves the lacune in conducting Clinical Trials and pre-
sents the Regulatory reforms in India. Methods: India is an emerging destination 
for Clinical Research because of its genetic pool, availability of patients for enrol-
ment, infrastructure and talented pool of physicians. In order to ensure patient 
safety in Clinical Trials several regulatory reforms have been implemented by the 
ministry of health and family welfare, Govt. of India. These include constitution of 
ethics committee’s, audio video recording of the consent, audit and inspections of 
the sites, registration of ethics committee’s etc. Compensation policy for deaths dur-
ing the clinical trials have been framed. In order to ensure patient safety, National 
Pharmacovigilance Programme of India (PvPI) have been launched in the country 
for the safety monitoring of drugs as a post marketing surveillance. PvPI is work-
ing in coordination with the WHO Uppsala Monitoring Centre. The presentation 
will discuss the salient regulatory reforms for patient’s safety in clinical research 
in India. Results: In order to ensure the safety of patients, the reporting culture 
of the Adverse Drug Reactions have been improved. There is a pool of 70000 ADR’S 
in the PvPI database and number of ADR Centres have been increased to 150 in 
various parts of the country. With the implementation of new Regulatory reforms, 
there is tranparency in the system. Culture of Reporting ADR’S by the physicians 
have also increased. The Ethical Review Boards have been prooperly strengthened, 
Serious Adverse Drug Reactions are being reported to the regulatory agency and 
compensations are being paid in the Clinical Trials. ConClusions: It is concluded 
that the new Regulatory Reforms will ensure the safety of the patients during the 
Clinical Trials.
PHP20
dRug utilization PatteRn foR tHe tReatment of sePtic sHock in 
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objeCtives: To describe the drug utilization pattern in the treatment of patients 
with septic shock in the ICU. Methods: Setting: 7-bed mixed medical/surgical 
intensive care unit (ICU) of a tertiary care teaching hospital. A retrospective cohort 
study of patients with septic shock, who were treated in the ICU between January 
2012 and December, 2013. The ICU database was used to identify the patients. The 
patient demographics and characteristics were recorded. In addition, the number 
and type of prescribed medications, type of infection, and culture results were deter-
mined. The main outcomes were the type of medication classes utilized and their 
comparison between the survivors & non-survivors. Results: During the study 
period, 109 cases were identified. Upon presentation, the mean Acute Physiology 
and Chronic Health Evaluation II (APACHE II) score was 22.5 (SD ±7.8), 93 (85.3 %) 
patients had leucocytosis, and 84 (77.0 %) had positive cultures. The mean num-
ber of medications prescribed per patient was 11.7 (SD ±4.7). The most commonly 
prescribed medication classes were proton pump inhibitors, carbapenems, BL/BLI 
combinations and vasopressors prescribed in 101 (92.6 %), 75 (68.8 %), 64 (58.7 %), and 
91 (83.4 %) patients, respectively. Antifungals and blood products were prescribed 
in 45 (41.2 %) and 77 (70.6 %) patients, respectively. Medication usage were higher 
in non-survivors, compared to survivors (12.6 ± 2.4 versus 9.7±4.1), and in patients 
with positive cultures (13.5±1.9 versus 9.3± 3.6) compared to patients with negative 
cultures. ConClusions: In patients with severe sepsis and septic shock, multiple 
medications were prescribed, and the use of medications was higher in the non-
survivors in comparison to the survivors.
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objeCtives: Jos loss has been shown to negatively affect displaced workers’ 
health. But it remains unclear how job loss affects medication use and spending 
on prescription drugs. The purpose of this study was to examine the impact of job 
loss on the use of medications as measured by out-of-pocket payment for the last 
prescription. Methods: A quasi-experimental design was used to study workers 
who did and did not experience involuntary job displacement. The data was drawn 
from four waves of the Medical Expenditure Panel Survey (MEPS), taken in 2008, 
2009, 2010, and 2011. Involuntary job loss was defined as job separation due to 
“job ended” or “business dissolved or sold”. Our analysis was limited to adults who 
participated in all five rounds of interviews. Results: While the average out-of-
pocket payment for the last prescription remained unchanged for those remained 
employed (around $23.10), the spending for those lost job increased by $2.82 ($19.41 
vs. $22.23). Compared with those who remained employed, those who experienced 
to 71.45% because of unfair competition between pharmaceutical distribution 
companies and cooperation failure between pharmaceutical manufacturers and 
pharmaceutical suppliers. ConClusions: Successful pharmaceutical supply sys-
tem of essential medicines needs to clearly define the function and to coordinate 
competition and cooperation relationship between pharmaceutical manufacturers, 
distribution companies and township hospitals. KeywoRds: essential medicine; 
availability; organizational arrangement.
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objeCtives: There have been several strict cost containment measures, as refer-
ence pricing system and global budget, being aplied in Turkish health care system 
especially for drugs. As a result of these measures; most of the drugs being marketed 
in Turkey have the lowest price in Europe. In this regard, several drugs including 
the drugs being used in critical diseases such as cancer, orphan diseases etc, have 
been withdrawn from the market or even they wouldn’t be able to enter the market. 
Therefore, Turkish government brings these drugs from abroad by paying much 
more money compared to the current or the future prices (the price if the drug 
would have licenced or being reimbursed) of those drugs in Turkey. The aim of this 
study is to analyze the list of these drugs according to their ATC groups. Methods: 
The list of Social Security Institution (SSI) on drugs bringing from abroad (Annex 4 
C) have been analyzed in assistance with RxMediaPharma® Program. Results: In 
total, there are 662 drugs being listed in the latest Annex 4-C list. Among this list; 
the most frequently listed ATC group is L (antineoplastic and immunomodulating 
agents) by 22%, second is A (alimentary tract and metabolism) by 13.3%, third is C 
(cardiovascular system) by 12.5%, fourth and fifth are; N (nervous system) by 12% 
and J (antiinfectives for systemic use) by 6,35% relatively. ConClusions: Strict 
cost containment measures being applied in Turkey causes shortages of several 
drugs especially the ones being used in diseases with high mortality rates like 
cancer. In this situation, despite government has brought these medicines from 
abroad, as this procedure takes some time, patients may have trouble in reaching 
these drugs on time and SSI pays much more for these drugs compared to their 
probable prices in Turkey.
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objeCtives: Pharmacoeconomics and outcomes research (PEOR) has emerged as 
a key decision-making tool to optimize patient care and add value to health care 
services. Considering the strategic importance of Asian markets and economic con-
straints in the pharmaceutical sector, an understanding of current pricing strategies 
become vital for market authorization holders as well as payers. Methods: An 
assessment of health care policies, pricing systems, and reforms impacting reim-
bursement and market access environment was undertaken across major Asian 
markets (Japan, China, South Korea, and India). Information sources included online 
portals of regulatory agencies and relevant keyword searches. Results: Health 
policy decisions over recent years have indicated varying levels of priorities and 
interests within Asia. Japan continues to increase health care investments and 
attempts are being made to expedite drug approval process. Despite a robust pricing 
mechanism, Japanese pharmacoeconomic guidelines are yet to be implemented. 
Public health expenditure in China has witnessed almost 50% growth since 2004. 
Chinese pharmacoeconomic guidelines are now in practice and pricing norms 
have gained more structure with the introduction of external referencing and price 
negotiations with drug companies. In South Korea, pharmacoeconomic guidelines 
are well-established and the current focus is on cost-containment measures like 
profit controls and price cuts. Pharmacoeconomics in India is still in its nascent 
stage but the 2013 Drugs (Prices Control) Order (DPCO) included radical changes 
focussing on market-based pricing. Furthermore, the introduction of price negotia-
tion mechanisms is also being considered by the Department of Pharmaceuticals 
(DoP) in India. ConClusions: The focus on PEOR by reimbursement agencies in the 
West has compelled their Asian counterparts to revisit pricing policies. Japan has 
started drafting pharmacoeconomic guidelines, while Chinese and South Korean 
governments have implemented new mechanisms to manage drug prices. In India, 
the DoP has encouraged revisions in the DPCO and further reforms in pricing mecha-
nisms are expected in the near future.
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objeCtives: In China, maximum retail prices of reimbursed medicines are con-
trolled at the national level by the National Development and Reform Commission 
(NDRC). At the provincial level, different tendering processes are used to procure 
medicines, often resulting in disparity between provinces and a significantly lower 
final price than the MRP. The objective of this research is to understand the dif-
ferent provincial tendering models and evaluate the resultant effect on medi-
cine prices. Methods: We conducted secondary research of both national and 
provincial government websites to identify the different tendering models used 
across China. Provincial tender results were analyzed to understand the final 
price variation between provinces, relative to the MRP. Finally, primary research 
was conducted with payers in provinces with well-established tendering models - 
including Anhui, Beijing, Fujian, Hebei and Shanghai - to understand the individual 
nuances. Results: Tendering models exist on a continuum between “price focused” 
and “quality focused” processes. The former includes both the Anhui and Fujian 
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perspectives on CAM was the lack of scientific evidences. The attitudes on CAM were 
basically shaped based on their personal CAM use rather than knowledge gained 
during an academic course. Lack of knowledge on CAM was also attributing to the 
doctors’ reluctance in CAM discussion with their patients. Though addition of CAM 
courses into the medical curriculum was proposed by some of the doctors; the prac-
tical implication was criticized as some found medical curriculum heavily packed 
with the biomedical courses. ConClusions: Majority of the doctors in this study 
were skeptical and uncertain about CAM due to lack of scientific evidence. Doctor-
patient communication on CAM can only be improved when doctors’ knowledge 
on CAM can be improved by providing necessary training on CAM.
HealtH caRe use & Policy studies – equity and access
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objeCtives: Non-Hispanic Blacks and Hispanics are less likely than non-Hispanic 
Whites to be eligible for U.S. Medicare medication therapy management (MTM) 
services. The objectives for this study were to determine (1) racial/ethnic dispari-
ties in meeting MTM eligibility criteria as stipulated in the Patient Protection and 
Affordable Care Act (PPACA); and (2) whether there would be greater disparities in 
health/economic outcomes among MTM-ineligible than MTM-eligible groups (if 
so, the PPACA MTM eligibility criteria may aggravate existing disparities in these 
outcomes). Methods: Medicare Current Beneficiaries Survey (2007-2008) was ana-
lyzed. PPACA MTM eligibility was compared between Whites and minorities using 
logistic regression. Various other regression models were used for other study out-
comes (measures for health status, health services utilization/costs and medication 
utilization patterns). To determine difference in disparities across MTM eligibility 
categories, interaction terms were included between dummy variables for race/
ethnicity and MTM eligibility and were interpreted on the multiplicative term and 
using marginal effects. Results: The sample consisted of 12,966 Medicare benefi-
ciaries (weighted to 51,635,149). Blacks and Hispanics were less likely than Whites 
to meet PPACA MTM eligibility criteria (adjusted odds ratio [OR] = 0.66 [P< 0.05] for 
Blacks, and OR= 0.62 [P< 0.05] for Hispanics). Racial and ethnic disparities in self-
perceived health status (SPHS), activities of daily living (ADLs), and instrumental 
ADLs were greater among the MTM-ineligible than the MTM-eligible populations 
(e. g., for SPHS, difference in marginal effects between Whites and Blacks= 27.25 
[P< 0.01] across MTM eligibility categories, and between Whites and Hispanics= 20.62 
[P= 0.03] ). Disparities were smaller in number of chronic conditions and number and 
costs of physician visits among MTM-ineligible compared to MTM-eligible popula-
tions. No other variables exhibited significant interaction effects. ConClusions: 
The PPACA MTM eligibility criteria is not an ideal alternative in resolving disparity 
issues associated with Medicare MTM eligibility criteria. MTM eligibility criteria 
which reduce rather than aggravate disparities have yet to be identified/devised.
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objeCtives: To conduct a survey of the possible factors that cause the tension 
between patients and doctors. Methods: The survey including 16 items (8 for 
patients and 8 for doctors) was conducted in one of the Level A hospitals in south-
west region of China for a total of 853 questionnaires with 580 for patients and 273 
for doctors respectively. Microsoft Excel 2007 was used to perform data extraction and 
analysis. Results: The survey yielded to 822 questionnaires with a 96.37% response 
rate. Most of the patients (93.19%) want doctors to seek their opinions when providing 
the treatment. While 61.48% doctors indicated it was difficult to share decision-mak-
ing with patients. Account for 60.47% patients would like to obtain information from 
doctors. Whereas, 52.75% of doctors expressed that it was difficult to provide patient 
with high quality and reliable evidence or information. Twenty percent of the patients 
didn’t fully satisfied with the existing treatment, while 63% doctors indicated that it 
was difficult to meet patients’ desire. The reasons for the difficulty in communication 
were mainly about: short communication time (50.48%) and improper communica-
tion method (37.07%). Only 14.61% of doctors expressed that they had enough time to 
communicate with patients. ConClusions: Lack of ‘communication openness’ was 
identified as a major factor which hindered the shared decision-making, A successful 
bidirectional way to encourage shared decision-making to alleviate the current tense 
relationship for both sides is needed.
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intRoduCtion: (1) Since 2009 China had implemented national essential drug 
system, and issued first and second edition of NEDL (National Essential Drugs List) 
respectively in 2009 and 2013, which respectively covered 307 drugs and 520 drugs. 
(2) With development of Chinese health care reform, planning low-priced drug policy 
and adjusted essential drug system will impact on drug access. objeCtives: To 
describe Chinese policies’ development for promoting drug access, analyze the 
policies’ impact and potential lacks. Methods: Through collecting relevant poli-
cies from national departments and 31 provinces, apply descriptive statistics and 
comparison to summarize these policies’ impact. Results: (1) On May 2013 China 
involuntary job separation were significantly more likely to report zero expense on 
prescription drugs (odds ratio 1.37, 95% confidence interval (CI) 0.1. 11-1.71). Among 
those with non-zero drug expenses, job loss was associated with 12.8% increase in 
the out-of-pocket payment for the last prescription while controlling for personal 
characteristics and the prescription payment before the job loss. ConClusions: 
The findings from this study indicates that impacts of job loss may vary based on 
the health status of workers. Job loss may discourage workers from initiating drug 
treatment. For those already on medications, job loss is linked with an increase 
in drug expenses. It is unclear the increase is caused by the worse health status 
after job loss or the use of medications to replace other more costly medical care.
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objeCtives: Technological change in medicine has been a major cause of rising 
health care expenditures in many countries. The adoption of new drugs plays an 
important role in accounting for the growth of spending on prescription drugs. 
This paper uses the prescription drug market in Taiwan as an example to investi-
gate the evolution of prices and quantities of new drugs. Methods: A new drug 
is defined in our study as one that was included in the NHI formulary after 1996. 
The study sample includes new molecules, new formulations, combinations, and 
indications till 2006. We run a cross-sectional equation for the launch price of new 
NMEs, and a panel regression for price ratio of current price versus the launch prices. 
Furthermore, we run a panel regression model for both sales and market share of 
new drugs. Results: The preliminary results show that the degree of competition 
in a therapeutic market is weakly associated with the launch price, but negatively 
associated with the price ratio. The pioneer product can maintain a relatively higher 
price ratio in a longer period, but the price ratio of new drugs for chronic diseases 
decreases more than that for acute diseases. The competition of therapeutic mar-
ket increases the sales, but decreases the market share of new drugs. The pioneer 
product has a positive impact on the sales and market shares of new drugs. The 
sales of new drugs for chronic diseases are higher than that for acute diseases, but 
the growth of market share of new drugs for chronic diseases is lower than that for 
acute diseases. ConClusions: The competition in the therapeutic market does 
not affect the regulated prices at the time of entry, but decreases the price ratios 
over time. The characteristics of new drugs are the major factors affecting market 
expansion and market substitution of new drugs.
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objeCtives: As the majority of the Indian population still residing in India it is not 
only imperative to the pharmaceutical companies marketing medicines to foray in 
to the rural market. But there is very less understanding of the actual potential and 
preferences of the rural health care practitioners. Hence in this study an attempt is 
made to understand the prescriber potential and to also to know the preferences 
of health care practitioners towards the company representative visits. Methods: 
A questionnaire based survey was designed to study the prescriber potential in 211 
villages of Belgaum district of Karnataka State in India. The survey included semi 
structured questionnaire aimed at 191 physicians and 75 chemists. The data form 
the questionnaire was coded transferred to SPSS software to analyze. The data is 
summarized by descriptive statistics. Results: It was also found that most 44% of 
the doctors are in age group of 20 to 30 and only 11% doctors are well experienced. 
40% of the doctors consult average 35 patients daily. In Belgaum rural area 65% 
doctors preferred amoxicillin in case of bacterial infection and also 31% cefixime. 
The prescriber interviews also revealed the interest of prescribers towards updat-
ing their knowledge by Continuous Medical Education (CME) and also doctors are 
interested for tele-marketing calls to know the scientific information. Stockiest 
of Belgaum visits about 66% of the retail shops, hence product availability is not 
a problem. ConClusions: In India, there is a potential in rural market form the 
selected category like anti-infective, antipyretic, pain management and cough 
therapy products.
PHP25
a Qualitative exPloRation of malaysian doctoRs’ PeRcePtions 
towaRds comPlementaRy and alteRnative medicines (cam)
Farooqui M.1, Othman C.N.2, Hassali A.A.3, Saleem F.3, Ul Haq N.3, Sadeeqa S.4
1Universiti Teknologi MARA, Penang, Malaysia, 2Universiti Teknologi MARA, Pulau Pinang, 
Malaysia, 3Universiti Sains Malaysia, Penang, Malaysia, 4Universiti Sains Malaysia (USM), 
Pinang, Malaysia
objeCtives: The study aims to assess doctors’ perceptions towards Complementary 
and Alternative Medicines (CAM) in their medical practice, factors that affect the 
referral of CAM and suggestions to improve CAM in medical practice. Methods: 
A qualitative research approach was adopted to gain a better understanding of the 
current perceptions and practice held by doctors’ within their medical professions. 
In order to gain a wide perspective of the issue, eleven doctors were purposively 
selected who were working in academics, hospitals and in the community health 
clinics. Participants were interviewed using a semi-structured interview guide. A 
saturation point was reached after the 10th interview, and no new information 
emerged with the subsequent interviews. All interviews were transcribed verbatim 
and analyzed by means of a standard content analysis framework. Results: The 
doctors expressed a range of views on CAM that can be divided into two major 
themes: doctors’ knowledge and understanding towards CAM and doctors’ view-
point on CAM in their professional practice. A key factor which affected doctor’s 
